Government-Owned Inventions; Availability for Licensing, 54583 [2016-19419]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 158 / Tuesday, August 16, 2016 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, 9609 Medical Center Drive,
Room 7W260, Rockville, MD 20892–9750,
240–276–5856, nadeem.khan@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 10, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–19416 Filed 8–15–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health.
ACTION: Notice.
AGENCY:
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:36 Aug 15, 2016
Jkt 238001
Email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Human Monoclonal
Antibodies Targeting Glypican-2 in
Neuroblastoma.
Keywords: Glypican-2, GPC2,
Antibody, Immunotoxin, Recombinant
Immunotoxin, RIT, Chimeric Antigen
Receptor, CAR, Antibody-drug
Conjugate, ADC, bispecific antibody,
neuroblastoma.
Description of Technology:
Neuroblastoma is a rare pediatric cancer
that affects one in every hundred
thousand children under the age of
fifteen in the United States. Current
standards of care are chemotherapy and
surgery, followed by stem-cell
treatments, radiation and antiganglioside antibody therapy, which
yield an average three-year survival rate
of 10–45%. This demonstrates a need
for more effective therapies.
Glypican-2 (GPC2) is a cell surface
protein that has been shown to be
preferentially expressed on numerous
pediatric cancers, including
neuroblastoma. Due to this preferential
expression, GPC2 represents a potential
candidate for targeted therapy.
Researchers at the National Cancer
Institute’s Laboratory of Molecular
Biology (NCI LMB) have developed and
isolated several single domain
monoclonal human antibodies against
GPC2. This technology covers the naked
GPC2 antibodies as well as their use as
targeting domains in recombinant
immunotoxins (RITs) and chimeric
antigen receptors (CARs). RITs (using
clones LH1, LH4, or LH7) and CARs
(using LH7) have shown specific killing
activity against GPC2-expressing cells,
suggesting that these candidates may be
further developed as therapeutics.
The technology has been validated
with in-vitro studies (human anti-GPC2
RITs and CARs can bind to, and kill,
GPC2-positive tumor cells) and the
researchers are currently developing
mouse models to further develop GPC2targeted therapies.
Potential Commercial Applications:
—Therapeutic applications include:
Unconjugated antibodies, and use as
targeting moieties for
immunoconjugates such as CARs,
ADCs, immunotoxins, and bispecific
antibodies
—Diagnostic agent for detecting and
monitoring target-expressing
malignancies
Value Proposition:
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
54583
—First to market potential—No current
clinical trials with GPC2-targeted
therapies
—Human antibody with high specificity
and binding to targets results in less
non-specific cell killing, therefore
fewer potential side-effects for the
patient
—Small size of single domain
antibodies enhances stability,
solubility, and target recognition
Development Stage: In-vitro.
Inventor(s): Mitchell Ho (NCI), et al.
Intellectual Property: US Provisional
Application 62/369,861 (HHS Reference
No. E–211–2016/0–US–01) filed August
2, 2016, entitled ‘‘Human Monoclonal
Antibodies Targeting Glypican-2 in
Neuroblastoma.’’
Collaboration Opportunity:
Researchers at the NCI seek parties
interested in licensing or co-developing
GPC2 antibodies and/or conjugates.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: August 8, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–19419 Filed 8–15–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Advisory Committee for Women’s
Services; Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given of a meeting of
the Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Advisory Committee for Women’s
Services (ACWS) on August 24, 2016.
The meeting will include discussions
on child welfare and substance use
disorders among families; improving the
health of women and girls; recoveryoriented systems of care and what they
mean for women; accountable health
communities and how they relate to
behavioral health; and a conversation
with the SAMHSA Deputy of
Operations and the Chief of Staff.
The meeting is open to the public and
will be held at SAMHSA, 5600 Fishers
Lane, Rockville, MD 20857, in
Conference Room 5N76. Attendance by
the public will be limited to space
available. Interested persons may
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 81, Number 158 (Tuesday, August 16, 2016)]
[Notices]
[Page 54583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-19419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850-9702, Tel. 240-276-5515 or Email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Human Monoclonal Antibodies Targeting Glypican-
2 in Neuroblastoma.
Keywords: Glypican-2, GPC2, Antibody, Immunotoxin, Recombinant
Immunotoxin, RIT, Chimeric Antigen Receptor, CAR, Antibody-drug
Conjugate, ADC, bispecific antibody, neuroblastoma.
Description of Technology: Neuroblastoma is a rare pediatric cancer
that affects one in every hundred thousand children under the age of
fifteen in the United States. Current standards of care are
chemotherapy and surgery, followed by stem-cell treatments, radiation
and anti-ganglioside antibody therapy, which yield an average three-
year survival rate of 10-45%. This demonstrates a need for more
effective therapies.
Glypican-2 (GPC2) is a cell surface protein that has been shown to
be preferentially expressed on numerous pediatric cancers, including
neuroblastoma. Due to this preferential expression, GPC2 represents a
potential candidate for targeted therapy. Researchers at the National
Cancer Institute's Laboratory of Molecular Biology (NCI LMB) have
developed and isolated several single domain monoclonal human
antibodies against GPC2. This technology covers the naked GPC2
antibodies as well as their use as targeting domains in recombinant
immunotoxins (RITs) and chimeric antigen receptors (CARs). RITs (using
clones LH1, LH4, or LH7) and CARs (using LH7) have shown specific
killing activity against GPC2-expressing cells, suggesting that these
candidates may be further developed as therapeutics.
The technology has been validated with in-vitro studies (human
anti-GPC2 RITs and CARs can bind to, and kill, GPC2-positive tumor
cells) and the researchers are currently developing mouse models to
further develop GPC2-targeted therapies.
Potential Commercial Applications:
--Therapeutic applications include: Unconjugated antibodies, and use as
targeting moieties for immunoconjugates such as CARs, ADCs,
immunotoxins, and bispecific antibodies
--Diagnostic agent for detecting and monitoring target-expressing
malignancies
Value Proposition:
--First to market potential--No current clinical trials with GPC2-
targeted therapies
--Human antibody with high specificity and binding to targets results
in less non-specific cell killing, therefore fewer potential side-
effects for the patient
--Small size of single domain antibodies enhances stability,
solubility, and target recognition
Development Stage: In-vitro.
Inventor(s): Mitchell Ho (NCI), et al.
Intellectual Property: US Provisional Application 62/369,861 (HHS
Reference No. E-211-2016/0-US-01) filed August 2, 2016, entitled
``Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma.''
Collaboration Opportunity: Researchers at the NCI seek parties
interested in licensing or co-developing GPC2 antibodies and/or
conjugates.
Contact Information: Requests for copies of the patent application
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D.,
email: john.hewes@nih.gov.
Dated: August 8, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-19419 Filed 8-15-16; 8:45 am]
BILLING CODE 4140-01-P
